Comments on a proposed rule requiring drug companies to disclose pricing information in direct-to-consumer (DTC) TV ads drew both qualified support and strong opposition from predictable quarters in responses posted by the U.S. CMS on Monday. Arguments against the rule from industry and advocates for free commercial speech made clear likely lines of attack while positive feedback suggested in some cases that the rule wouldn't go far enough to clarify true out-of-pocket costs in a complex market.